Table of Contents
of managerial and operational experience in the healthcare industry and as an investor in healthcare related companies.
Jonathan Leff has served as a member of our board of directors since October 2014. Mr. Leff is a partner of Deerfield Management
Company, LP and chairman of the Deerfield Institute. Prior to joining Deerfield in 2013, Mr. Leff was with Warburg Pincus, LLC for more than 16 years where he led the
firm's investment efforts in biotechnology and pharmaceuticals. Mr. Leff currently serves on the board of directors of the Spinal Muscular Atrophy Foundation, the Biotechnology Industry
Organization, Friends of Cancer Research, and Nivalis Therapeutics, Inc., as well as on the board of advisors of Columbia University Medical Center. Mr. Leff received his A.B. from
Harvard University, and earned his M.B.A. from Stanford University Graduate School of Business. Our board of directors believes Mr. Leff is qualified to serve as a director based upon his
extensive experience in the pharmaceutical and biotechnology industry, including his almost 20 years of experience as a director of multiple public and private biotechnology companies.
Carole Nuechterlein has served as a member of our board of directors since October 2014. Ms. Nuechterlein joined
F. Hoffmann-La Roche Ltd. in 2002 and currently serves as a deputy director and head of the Roche Venture Fund. Prior to that, Ms. Nuechterlein served as general counsel for
SangStat, Inc. She currently serves on the board of directors for Lysosomal Therapeutics Inc. Ms. Nuechterlein holds a B.A. from Valparaiso University and a J.D. from University
of Michigan. Ms. Nuechterlein was appointed to serve on our board of directors based upon her extensive experience in the pharmaceutical and biotechnology industry, including ten years of
an attorney in the pharmaceutical and biotechnology industry and over ten years of experience as an investor in life science companies.
Bong Koh has served as a member of our board of directors since June 2015. Since 2009, Dr. Koh has been a partner at Venrock, a
venture capital firm where he manages Venrock's public and cross-over biotechnology fund. Dr. Koh earned his B.A. from Yale University, his M.D. from the University of California, San
Francisco, and an M.B.A. from Harvard Business School. Our board of directors believes that Dr. Koh should serve as a director based on his extensive experience in the biotechnology industry
providing leadership in biotechnology investments.
Frank Verwiel has served as a member of our board of directors since December 2015. Dr. Verwiel was the President and CEO of
Aptalis Pharma Inc. from 2005 to 2014, where he also served on the board of directors. He currently serves as a member of the board of directors of Achillion Pharmaceuticals, Inc., a
position he has held since December 2015, and is an observer to the board of directors of Bavarian Nordic A/S. Dr. Verwiel previously served on the board of directors of
InterMune, Inc. from 2012 to 2014. Dr. Verwiel was also a director of the Biotechnology Industry Organisation. Dr. Verwiel received his M.D. from Erasmus University, Rotterdam and
his M.B.A. from INSEAD. Our board of directors believes that Dr. Verwiel should serve as a director based upon his scientific acumen and his over 25 years of strategic, operational and
international experience in the pharmaceutical industry.
Scientific Advisory Board
We have established a scientific advisory board. We regularly seek advice and input from these experienced leaders on matters related
to our research and development programs. Our scientific advisory board consists of experts across a range of key disciplines relevant to our programs and science. We intend to continue to leverage
the broad expertise of our advisors by seeking their counsel on important topics relating to our research and development programs. The members of our scientific advisory board have entered into
agreements with us covering confidentiality and non-disclosure matters. Our scientific advisory board currently consists of our Chief Scientific Officer Dr. Kaspar (Nationwide Children's Hospital),
Christian Lorson, Ph.D.